Publications
Peer-reviewed publications
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry
Clinical and Experimental Dermatology (March 2024) DOI
2024
Patterns in the Sequential Treatment of Patients With Rheumatoid Arthritis Starting a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: 10-Year Experience From a US-Based Registry
ACR Open Rheumatology 6(1):5–13 (October 2023) DOI
2023
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.
Journal of Psoriasis and Psoriatic Arthritis 8(2):74–82 (March 2023). DOI
2023
Outcomes of Biologic Use in Asian Compared to non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.
Dermatology and Therapy (2022). DOI
2022
Poor patient-reported outcomes and impaired work productivity in patients with inflammatory bowel disease in remission.
Gastro Hep Advances 1(6):927–935 (2022). DOI
2022
Prospective Cohort Study of Psoriatic Arthritis Risk in Patients with Psoriasis in a Real World Psoriasis Registry.
Journal of the American Academy of Dermatology (2022), DOI
2022
Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry.
Dermatology and Therapy November 2022. DOI
2022
Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry.
Journal of Psoriasis and Psoriatic Arthritis April 2022. DOI
2022
Disease burden and patient-reported outcomes among ulcerative colitis patients according to therapy at enrollment into CorEvitas’ Inflammatory Bowel Disease Registry.
Crohn’s & Colitis 360 April 2022. DOI
2022
Regional Variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6-months following Biologic Initiation.
SKIN The Journal of Cutaneous Medicine 2022 Jan;6(1):41-43. DOI
2022
Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States.
JID Innovations (2021);1:100025 DOI
2021
Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis registry.
J Drugs Dermatol. 2020 Nov 1;19(11):1119-1122. DOI.
2020
Drug Survival of Ixekizumab, TNF Inhibitors, and other IL-17 inhibitors in Real World Patients with Psoriasis: The Corrona Psoriasis Registry.
Dermatol Ther. 2021 Mar;34(2):e14808. DOI. Epub 2021 Feb 15.
2020
Disease Response and Patient Reported Outcomes Among Initiators of Ixekizumab.
J Dermatolog Treat. 2020 Dec 2;1-9. DOI.
2020
Understanding characteristics of patients newly initiating ixekizumab: Findings from the Corrona Psoriasis Registry.
J Comp Eff Res. 2021 Feb;10(2):157-167. DOI. Epub 2020 Dec 23.
2020
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Dermatology. 2020 Jan 21; 1-10. DOI.
2020
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Rheumatol Int. 2019 Sep; 39 (9): 1547-1558. DOI.
2019
Response to “Be alert to leukocyte antibodies when prescribing granulocyte transfusions”.
Transfusion. 2019 Jun; 59 (6): 2174-2175. DOI.
2019
WBC alloimmunization: effects on the laboratory and clinical endpoints of therapeutic granulocyte transfusions.
Transfusion. 2018 May; 58 (5): 1280-1288. DOI.
2018
No Obesity Paradox in Pediatric Patients With Dilated Cardiomyopathy.
ACC Heart Fail 2018 Mar; 6 (3): 222-230. DOI.
2018
Laboratory predictors of Bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO Trial.
Blood. 2017 Sep 7: 130 (10): 1247-1258. DOI.
2017
An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
Andrology 4(1):41-45, 2016. DOI.
2016
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone treated donors in neutropenic patients with infection.
Blood 126(18):2153-2161, 2015. DOI.
2015
Impact of PCA Strategies on Pain Intensity and Functional Assessment Measures in Adults with Sickle Cell Disease during Hospitalized Vaso-Occlusive Episodes.
Amer J Hematol 87(10):E71-74, 2012. DOI.
2012
Posters, abstracts & presentations
Treatment Patterns Among patients With a History of Moderate to Severe Ulcerative Colitis in CorEvitas’ Inflammatory Bowel Disease Registry.
The American Journal of Gastroenterology 116(1):S1379–S1380 (October 2021). DOI
2021
Psoriatic arthritis risk in psoriasis patients in the Corrona Psoriasis Registry.
Journal of Investigative Dermatology: Volume 141, Issue 5, Supplement, S53, 2021 May 1. DOI
2021
Characterizing Prior Healthcare Resource Utilization by Disease Severity in Ulcerative Colitis: Real World Data From the Corrona Inflammatory Bowel Disease Registry.
The American Journal of Gastroenterology: October 2020 - Volume 115 - Issue - p S346-347. DOI
2020
Differences in Clinical Characteristics and Patient-Reported Outcomes of Recently Hospitalized vs Non-Hospitalized Ulcerative Colitis Patients: Real World Data From Corrona Inflammatory Bowel Disease Registry.
The American Journal of Gastroenterology: October 2020 - Volume 115 - Issue - p S347-348. DOI
2020
Characterizing prior healthcare resource utilization by disease severity in Crohn’s disease: real-world data from the Corrona Inflammatory Bowel Disease Registry
J Manag Care Spec Pharm, 2020 Oct;26(10-a Suppl):S62. DOI
2020
Differences in Clinical Characteristics and Patient-Reported Outcomes of Recently Hospitalized vs Non-Hospitalized Crohn’s Disease Patients: Real World Data From Corrona Inflammatory Bowel Disease Registry.
J Manag Care Spec Pharm, 2020 Oct;26(10-a Suppl):S61-S62. DOI
2020
Real World Treatment Patterns and Treatment Persistence Among Ulcerative Colitis and Crohn’s Disease Patients in the Corrona Inflammatory Bowel Disease National Registry.
The American Journal of Gastroenterology: October 2020 - Volume 115 - Issue - p S452. DOI
2020
Poor Patient-Reported Outcomes were Observed in Patients in the Corrona Inflammatory Bowel Disease Registry, despite being in Clinical Remission.
Gastroenterology 158 (6): S-662-S-663. DOI.
2020
Enrollment Characteristics of Ulcerative Colitis and Crohn’s Disease Patients in the Corrona Inflammatory Bowel Disease Registry According to Type of Insurance.
Gastroenterology. 158 (6): S-733-S-734. DOI.
2020
Considerable Work Productivity Loss in Patients with Inflammatory Bowel Disease both with Active Disease and in Clinical Remission.
Gastroenterology 158 (6); S-663-S-664 May 2020. DOI.
2020
Disease Burden and Patient-Reported Outcome Measures Among Ulcerative Colitis Patients According to Therapy at Enrollment into the Corrona IBD Registry.
Gastroenterology. 158 (6); S-725-S-726 May 2020. DOI.
2020
Impact of Palmoplantar Psoriasis on Clinical and Patient Reported Outcomes; Results from the Corrona Registry.
Poster presentation at AAD Annual Meeting, San Diego CA, February 2018. DOI.
2018
Describing the Clinical and Patient Reported Outcomes of Patients with Scalp Psoriasis Enrolled in the Corrona Psoriasis Registry.
Poster presentation at AAD Annual Meeting, San Diego CA, February 2018. DOI.
2018
The Burden of Nail Psoriasis: A Real World Analysis from the Corrona Psoriasis Registry.
Poster presentation at AAD Annual Meeting, San Diego CA, February 2018. DOI.
2018
The Association of Growth Patterns and Clinical outcomes in Children with Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry Study Group.
Poster presentation at AHA Annual Meeting, Orlando FL, November 2015. DOI.
2015
A Randomized Controlled Trial on the Efficacy of High-Dose Granulocyte Transfusion Therapy in Neutropenic Patients with Infection [abstract].
Blood 2014 124:597; published ahead of print December 5, 2014. DOI
2014
Cost Tradeoffs of Low, Medium, and High Dose Platelet Transfusions.
Poster presentation at AABB Annual Meeting, Denver CO, 2013. DOI.
2013
Hierarchical Linear Modeling for the Analysis of Pain and Functional Assessment Measures During Hospitalized Vaso-Occlusive Episodes in Adults with Sickle Cell Disease.
Oral presentation at Sickle Cell Disease Symposium and Scientific Meeting, February 2012
2012